成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Vitamin D Related/Nuclear Receptor Autophagy Apoptosis Anti-infection Metabolic Enzyme/Protease
  2. Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite
  3. Kaempferol

Kaempferol  (Synonyms: 山奈酚; Kempferol; Robigenin)

目錄號: HY-14590 純度: 99.92%
COA 產品使用指南 技術支持

Kaempferol (Kempferol) 在乳腺癌細胞中抑制雌激素受體 (estrogen receptor α) 表達,在膠質母細胞瘤細胞和肺癌細胞中,通過激活 MEK-MAPK 誘導細胞凋亡。Kaempferol 可用于乳腺癌研究。

MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務

Kaempferol Chemical Structure

Kaempferol Chemical Structure

CAS No. : 520-18-3

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(單位)同一產品試用裝僅限申領一次,同一機構(單位)一年內

     可免費申領三個不同產品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數量
10 mM * 1 mL in DMSO ¥450
In-stock
50 mg ¥405
In-stock
100 mg ¥750
In-stock
200 mg ¥900
In-stock
500 mg ¥2000
In-stock
1 g   詢價  
5 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Kaempferol:

MCE 顧客使用本產品發(fā)表的 37 篇科研文獻

WB

    Kaempferol purchased from MCE. Usage Cited in: Biomed Pharmacother. 2023 Jan;157:114087.  [Abstract]

    Kaempferol (KPF; 100?μM; pretreat for 1 h) significantly inhibits the Doxorubicin (DOX)-induced increased expression of apoptosis-related proteins including cleaved-caspase3, p-P53, and reverses the decline of the ratio of Bcl2 to Bax, indicating that Kaempferol suppresses apoptosis in tubular epithelial cells.
    • 生物活性

    • 實驗參考方法

    • 純度 & 產品資料

    • 參考文獻

    生物活性

    Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].

    IC50 & Target[1]

    ERα

     

    Human Endogenous Metabolite

     

    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    > 1 x 10-4 M
    Compound: 7
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    Cytotoxicity against human A549 cells after 72 hrs by XTT assay
    [PMID: 20619940]
    A549 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    A549 IC50
    > 10 μM
    Compound: 5
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    [PMID: 28165740]
    A549 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    [PMID: 21106454]
    B16 IC50
    20 μM
    Compound: 10
    Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs
    Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs
    [PMID: 19615910]
    B16 IC50
    53.7 μM
    Compound: 11
    Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT assay
    [PMID: 25659770]
    B16-4A5 IC50
    25 μM
    Compound: 16
    Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs
    Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs
    [PMID: 20189399]
    B16-4A5 IC50
    88 μM
    Compound: 10
    Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability after 68 hrs by WST8 assay
    Inhibition of theophylline-stimulated mouse B16-4A5 cell proliferation assessed as cell viability after 68 hrs by WST8 assay
    [PMID: 19615910]
    BEAS-2B IC50
    0.35 mM
    Compound: 2
    Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 33231455]
    BGC-823 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human BGC-823 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human BGC-823 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    BT-549 IC50
    > 10 μM
    Compound: 5
    Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
    Cytotoxicity against human BT549 cells after 48 hrs by SRB assay
    [PMID: 28165740]
    BV-2 IC50
    8.86 μM
    Compound: 5
    Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay
    Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay
    [PMID: 28165740]
    Ca9-22 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human Ca9-22 cells by MTT assay
    Cytotoxicity against human Ca9-22 cells by MTT assay
    [PMID: 21106454]
    CHO-K1 IC50
    0.24 mM
    Compound: 2
    Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    Cytotoxicity against CHO-K1 cells assessed as reduction in cell viability after 24 hrs by MTT assay
    [PMID: 33231455]
    CWR22R IC50
    > 40 μM
    Compound: 19
    Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
    Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer
    [PMID: 22789812]
    HCC1937 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human HCC1937 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human HCC1937 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    HCT-116 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human HCT-116 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    HEK293 IC50
    1.2 μM
    Compound: 7h
    Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay
    Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay
    [PMID: 20731357]
    HEK293 IC50
    3.9 μM
    Compound: 21
    Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay
    Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay
    [PMID: 30943030]
    HeLa IC50
    > 1 x 10-4 M
    Compound: 7
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by XTT assay
    [PMID: 20619940]
    HeLa IC50
    2.4 μg/mL
    Compound: 6
    Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA
    Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA
    [PMID: 19942440]
    Hep 3B2 IC50
    17.74 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human Hep3B cells by MTT assay
    Cytotoxicity against human Hep3B cells by MTT assay
    [PMID: 21106454]
    HepG2 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    HepG2 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 21106454]
    HepG2 IC50
    > 400 μM
    Compound: 33
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 21726077]
    HepG2 EC50
    7.74 μM
    Compound: Kaempferol
    Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
    Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay
    [PMID: 26974372]
    HepG2 IC50
    9.64 μM
    Compound: 5
    Inverse agonist activity at human GAL4-DBD-fused ERRalpha-LBD transfected in human HepG2 cells assessed as disruption of interaction with PGC-1alpha after 24 hrs by dual luciferase reporter gene assay
    Inverse agonist activity at human GAL4-DBD-fused ERRalpha-LBD transfected in human HepG2 cells assessed as disruption of interaction with PGC-1alpha after 24 hrs by dual luciferase reporter gene assay
    [PMID: 23656512]
    HT-29 IC50
    > 1 x 10-4 M
    Compound: 7
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    Cytotoxicity against human HT-29 cells after 72 hrs by XTT assay
    [PMID: 20619940]
    Huh-7 CC50
    > 50 μM
    Compound: 26
    Cytotoxicity against human Huh7.5.1 cells by MTT assay
    Cytotoxicity against human Huh7.5.1 cells by MTT assay
    [PMID: 22445328]
    J774.2 IC50
    53.67 μM
    Compound: 1
    Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay
    Cytotoxicity against BALB/c mouse J774.2 cells after 72 hrs by trypan blue assay
    [PMID: 19489596]
    Jurkat IC50
    10.5 μM
    Compound: Kaempferol
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
    Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method
    [PMID: 30776692]
    Jurkat IC50
    11 μM
    Compound: Kaempferol
    Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
    Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method
    [PMID: 30776692]
    L929 EC50
    20 μM
    Compound: kaempferol
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining
    [PMID: 9287415]
    L929 EC50
    25 μM
    Compound: kaempferol
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
    Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay
    [PMID: 9287415]
    MCF7 IC50
    > 10 μM
    Compound: 2
    Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells measured after 48 hrs by MTT assay
    [PMID: 33979163]
    MCF7 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    [PMID: 21106454]
    MCF7 IC50
    50 μM
    Compound: Kaempferol
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
    [PMID: 33257172]
    MCF7 IC50
    6.2 μM
    Compound: 12
    Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
    Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
    [PMID: 21354800]
    MDA-MB-231 IC50
    > 20 μg/mL
    Compound: Kaempferol
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    [PMID: 21106454]
    MDCK CC50
    > 300 μM
    Compound: 3
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    Cytotoxicity against MDCK cells after 48 hrs by MTT assay
    [PMID: 19729316]
    MDCK IC50
    4.7 μM
    Compound: 12
    Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
    Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
    [PMID: 21354800]
    Monocyte IC50
    2.7 μM
    Compound: kaempferol
    Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
    Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
    [PMID: 8882428]
    Monocyte IC50
    20 μM
    Compound: Kaempferol
    Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA
    Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA
    [PMID: 10096854]
    MV4-11 GI50
    3.34 μM
    Compound: 5
    Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    [PMID: 23411073]
    Peritoneal macrophage IC50
    29 μM
    Compound: 5; kp19
    Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
    Inhibition of LPS-stimulated nitric oxide production in ddy mouse peritoneal macrophages measured after 20 hrs by Greiss method
    [PMID: 27955927]
    Platelet IC50
    > 50 μg/mL
    Compound: Kaempferol
    Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
    Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
    [PMID: 21106454]
    Platelet IC50
    3.55 μg/mL
    Compound: Kaempferol
    Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
    Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
    [PMID: 21106454]
    RAW264.7 IC50
    13.4 μM
    Compound: 5; kp19
    Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
    Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
    [PMID: 27955927]
    RAW264.7 IC50
    13.4 μM
    Compound: Kaempferol
    Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells pretreated for 2 hrs followed by LPS-stimulation after 16 hrs by Griess assay
    Inhibition of LPS-stimulated nitric oxide production in rat RAW264.7 cells pretreated for 2 hrs followed by LPS-stimulation after 16 hrs by Griess assay
    [PMID: 28662961]
    RAW264.7 IC50
    15 μM
    Compound: 5; kp19
    Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs
    Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells measured after 16 hrs
    [PMID: 27955927]
    RAW264.7 IC50
    17 μM
    Compound: 5; kp19
    Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
    Inhibition of LPS/INF-gamma-stimulated nitric oxide production in mouse RAW264.7 cells by Griess method
    [PMID: 27955927]
    RAW264.7 IC50
    60.2 μM
    Compound: 7
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method
    [PMID: 21353543]
    RAW264.7 IC50
    80.3 μM
    Compound: 7
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
    Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs
    [PMID: 21353543]
    RS4-11 GI50
    > 50 μM
    Compound: 5
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay
    [PMID: 23411073]
    Sf21 IC50
    > 100 μM
    Compound: 6
    Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay
    Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay
    [PMID: 17378609]
    SK-MEL-2 IC50
    > 10 μM
    Compound: 5
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay
    [PMID: 28165740]
    SK-OV-3 IC50
    > 10 μM
    Compound: 5
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay
    [PMID: 28165740]
    體外研究
    (In Vitro)

    Kaempferol 還通過抑制 Src 激酶和下調 NFκB 通路來抑制白細胞介素 4 和環(huán)加氧酶 2 的表達,從而具有抗炎作用。山奈酚還可有效抑制卵巢癌細胞的血管生成和誘導細胞凋亡[1]。Kaempferol 是一種天然黃酮類化合物,廣泛分布于水果和蔬菜中,前瞻性研究表明,幾十年來,食用 Kaempferol 可顯著降低美國女護士患卵巢癌的風險。經過 24 小時的處理后,Kaempferol 對所有 3 種受試卵巢癌細胞的增殖產生顯著的濃度依賴性抑制。在 40 μM 或更高濃度的處理時觀察到這種抑制作用[2]。Kaempferol 是一種類黃酮,廣泛存在于多種植物衍生食品和傳統(tǒng)藥物中使用的葉子中。Kaempferol 顯著抑制 NADPH 氧化酶活性。山奈酚通過直接結合 NADPH 氧化酶來減少活性氧 (ROS)。Kaempferol 通過降低 CAMKII 氧化來防止 Ang II 誘導的竇房結細胞死亡[3]。10 -20 μM Kaempferol 劑量依賴性地抑制其在致敏 RBL-2H3 細胞中的釋放。當將 10 -20 μM Kaempferol 補充到 DNP-BSA 攻擊的 RBL-2H3 細胞中 15 分鐘時,Syk 和 PLCγ 的激活被高度減弱。當向 DNP-BSA 攻擊的 RBL-2H3 細胞中加入 ≥10 μM Kaempferol 60 分鐘時,COX2 誘導減少[4]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    體內研究
    (In Vivo)

    COX2 誘導在 BSA 攻擊的 BALB/c 小鼠的氣道中得到證實。觀察到未處理的對照小鼠的氣道中缺乏 COX2。小鼠吸入 BSA 導致小鼠氣道中 COX2 誘導增強 (深棕色染色),這可通過口服山奈酚逆轉。在 BSA 攻擊的小鼠中,觀察到明顯的杯狀細胞增生和上皮增厚。當 BSA 攻擊小鼠補充 20 mg/kg Kaempferol 時,上皮增厚完全消失[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    分子量

    286.24

    Formula

    C15H10O6

    CAS 號
    性狀

    固體

    顏色

    Light yellow to yellow

    中文名稱

    山奈酚

    結構分類
    初始來源
    運輸條件

    Room temperature in continental US; may vary elsewhere.

    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數據
    細胞實驗: 

    DMSO 中的溶解度 : 20 mg/mL (69.87 mM; 超聲助溶; 吸濕的 DMSO 對產品的溶解度有顯著影響,請使用新開封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲備液
    濃度 溶劑體積 質量 1 mg 5 mg 10 mg
    1 mM 3.4936 mL 17.4679 mL 34.9357 mL
    5 mM 0.6987 mL 3.4936 mL 6.9871 mL
    查看完整儲備液配制表

    * 請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效
    儲備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲存時,請在1年內使用, -20°C儲存時,請在6個月內使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗:

    請根據您的 實驗動物和給藥方式 選擇適當的溶解方案。

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:
    ——為保證實驗結果的可靠性,澄清的儲備液可以根據儲存條件,適當保存;體內實驗的工作液,建議您現用現配,當天使用;
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2 mg/mL (6.99 mM); 澄清溶液

      此方案可獲得 ≥ 2 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 20.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2 mg/mL (6.99 mM); 澄清溶液

      此方案可獲得 ≥ 2 mg/mL(飽和度未知)的澄清溶液。

      1 mL 工作液為例,取 100 μL 20.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

      2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。

    以下溶解方案,請直接配制工作液。建議現用現配,在短期內盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比; 如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請依序添加每種溶劑: 50% PEG300    50% Saline

      Solubility: 10 mg/mL (34.94 mM); 懸濁液; 超聲助溶

    • 方案 二

      請依序添加每種溶劑: 0.5% CMC/saline water

      Solubility: 5 mg/mL (17.47 mM); 懸濁液; 超聲助溶

    動物溶解方案計算器
    請輸入動物實驗的基本信息:

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數量

    由于實驗過程有損耗,建議您多配一只動物的量
    請輸入您的動物體內配方組成:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網站選購。 ,Tween 80,均可在 MCE 網站選購。
    計算結果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
    您所需的儲備液濃度超過該產品的實測溶解度,以下方案僅供參考,如有需要,請與 MCE 中國技術支持聯系。
    動物實驗體內工作液的配制方法 : 取 μL DMSO 儲備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水
    連續(xù)給藥周期超過半月以上,請謹慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
    純度 & 產品資料

    純度: 99.92%

    參考文獻
    Kinase Assay
    [3]

    Right atria or sinus nodal cells are homogenized in lysis buffer consisting of (50 mM Tris-HCl pH 7.5, 100 mM KCl, 1 mM ethylenediamine tetraacetic acid, 1 mM ethylene glycol tetraacetic acid, 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 0.5 mM Benzamidine, 20 mg/L Leupeptin, 20 mM sodium pyrophosphate, 50 mM NaF, and 50 mM sodium β-glycerophosphate), and total protein content is determined by the Bradford assay. Caspase-3 activity is determined by EnzChek Caspase-3 Assay Kit[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [2]

    Ovarian cancer cells are seeded in 96-well plates at 2000 cells/well and incubated overnight before treatment with 0-160 μM Kaempferol for 24 hours in triplicates. The medium is removed, and the plates are freeze-thawed to lyse cells. Each well is added with 200 μL 1× CyQUANT cell lysis buffer containing 5x SYBR Green I and incubated at room temperature (RT) for 5 minutes. The reaction (50 μL) is transferred to PCR strip tubes and the fluorescent signal is measured at 90°C with a real-time Chromo4 PCR instrument. To ensure that cell proliferation assays are performed within a linear range of cell numbers, a standard curve is generated by seeding different amount of OVCAR-3 cells (based on counting with a hemacytometer) in a 96-well plate, and measuring genomic DNA abundance after overnight incubation. Three independent experiments are performed and data is pooled for statistical analysis[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [4]

    Mice[4]
    Three-week-old male BALB/c mice are randomly assigned to the four treatment groups as follows (n=8 per group). (1) PBS-sensitized mice; (2) BSA-sensitized mice; (3) BSA-sensitized and 10 mg/kg Kaempferol-administered mice; and (4) BSA-sensitized and 20 mg/kg Kaempferol-administered mice. Mice are given a commercial mouse chow diet containing 20.5% protein, 3.5% fat, 8% fiber, 8% ash, and 0.5% phosphorus and are allowed access to food and water ad libitum. The mice are kept under a 12 h light and dark cycle at 23±1°C with 50%±5% relative humidity in specific pathogen-free conditions. Mice are allowed to become accustomed to their surroundings for one week before starting the allergic experiments. Sensitization of all experimental mice is carried out by subcutaneous injection with 20 μg BSA in 30 μL PBS and 50 μL Imject Alum on days 0 and 14. The control mice are injected with a combination of 50 μL PBS and 50 μL Imject Alum without BSA. On days 28, 29, and 30, only the experimental mice sensitized to BSA are subject to inhalation of 5% BSA, while control mice are challenged with 5% PBS for 20 min in a plastic chamber connected to a Medel aerosol nebulizer. All mice are sacrificed 24 h after the last challenge. Whole blood samples are directly used to measure the contents of eosinophils, basophils and neutrophils. The right lung is stored in 4% paraformaldehyde until use.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    參考文獻

    完整儲備液配制表

    * 請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效
    儲備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲存時,請在1年內使用, -20°C儲存時,請在6個月內使用。

    可選溶劑 濃度 溶劑體積 質量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.4936 mL 17.4679 mL 34.9357 mL 87.3393 mL
    5 mM 0.6987 mL 3.4936 mL 6.9871 mL 17.4679 mL
    10 mM 0.3494 mL 1.7468 mL 3.4936 mL 8.7339 mL
    15 mM 0.2329 mL 1.1645 mL 2.3290 mL 5.8226 mL
    20 mM 0.1747 mL 0.8734 mL 1.7468 mL 4.3670 mL
    25 mM 0.1397 mL 0.6987 mL 1.3974 mL 3.4936 mL
    30 mM 0.1165 mL 0.5823 mL 1.1645 mL 2.9113 mL
    40 mM 0.0873 mL 0.4367 mL 0.8734 mL 2.1835 mL
    50 mM 0.0699 mL 0.3494 mL 0.6987 mL 1.7468 mL
    60 mM 0.0582 mL 0.2911 mL 0.5823 mL 1.4557 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產品:

    Your information is safe with us. * Required Fields.

       產品名稱:

     

    * 需求量:

    * 客戶姓名:

     

    * Email:

    * 電話:

     

    * 公司或機構名稱:

       留言給我們:

    Bulk Inquiry

    Inquiry Information

    產品名稱:
    Kaempferol
    目錄號:
    HY-14590
    需求量: